BR0209332A - Derivados de ftalazina com atividade inibidora da angiogênese - Google Patents
Derivados de ftalazina com atividade inibidora da angiogêneseInfo
- Publication number
- BR0209332A BR0209332A BR0209332-4A BR0209332A BR0209332A BR 0209332 A BR0209332 A BR 0209332A BR 0209332 A BR0209332 A BR 0209332A BR 0209332 A BR0209332 A BR 0209332A
- Authority
- BR
- Brazil
- Prior art keywords
- formula
- treatment
- compound
- sub
- oxide
- Prior art date
Links
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 title abstract 2
- 230000033115 angiogenesis Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 150000001204 N-oxides Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 abstract 1
- 208000025747 Rheumatic disease Diseases 0.000 abstract 1
- 108091008605 VEGF receptors Proteins 0.000 abstract 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 abstract 1
- 239000004037 angiogenesis inhibitor Substances 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000000552 rheumatic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
"DERIVADOS DE FTALAZINA COM ATIVIDADE INIBIDORA DA ANGIOGêNESE". A invenção refere-se aos novos derivados de ftalazina de fórmula I, em que R~ 1~ e R~ 2~ a) são independentemente, em cada caso, uma alquila inferior; b) juntos formam uma ponte de subfórmula I*, em que a ligação é obtiva através dos dois átomos de C-terminal e m é 0 a 4, ou c) juntos formam uma ponte de subfórmula I**, em que um ou dois dos elementos do anel T~ 1~, T~ 2~, T~ 3~ e T~ 4~ são nitrogênio, e os outros são, em cada caso, CH, e a ligação é obtida via os átomos T~ 1~ e T~ 4~; A, B, D, E e T são independentemente N ou CH sujeitos à condição que pelo menos um e não mais do que três destes radicais sejam N; X é imino, oxa, ou tia; Y é hidrogênio, arila substituída ou não-substituída, heteroarila substituída ou não-substituída, ou cicloalquila não-substituída ou substituída; e em que as ligações caracterizadas na subfórmula I* por uma linha ondulada são ligações simples ou duplas; a um N-óxido de um composto de fórmula I; um tautómero ou mistura de tautómeros de um composto de fórmula I ou um N-óxido do mesmo; e um sal farmaceuticamente aceitável de um composto de fórmula i, de um N-óxido ou de um tautómero ou mistura de tautómeros do mesmo; aos processos para a preparação do mesmo, a sua aplicação em um processo para o tratamento do corpo humano ou animal, ao uso do mesmo sozinho ou em combinação com um ou mais outros compostos farmaceuticamente ativos para o tratamento especialmente de uma doença que responda à inibição especialmente da quinase receptora para o fator de crescimento endotelial vascular, preferivelmente o tratamento de uma doença proliferativa, ou o tratamento de artrite inflamatória reumática ou reumatóide e/ou dor; e ao uso de um tal composto sozinho ou em combinação com um ou mais outros compostos farmaceuticamente ativos para a manufatura de uma preparação farmacêutica para o tratamento das ditas doenças em um animal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0111078.2A GB0111078D0 (en) | 2001-05-04 | 2001-05-04 | Organic compounds |
PCT/EP2002/004892 WO2002090346A1 (en) | 2001-05-04 | 2002-05-03 | Phthalazine derivatives with angiogenesis inhibiting activity |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0209332A true BR0209332A (pt) | 2004-07-20 |
Family
ID=9914117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0209332-4A BR0209332A (pt) | 2001-05-04 | 2002-05-03 | Derivados de ftalazina com atividade inibidora da angiogênese |
Country Status (12)
Country | Link |
---|---|
US (3) | US7399761B2 (pt) |
EP (1) | EP1387836B1 (pt) |
JP (1) | JP4365586B2 (pt) |
CN (1) | CN1314681C (pt) |
AT (1) | ATE393152T1 (pt) |
BR (1) | BR0209332A (pt) |
CA (1) | CA2446051A1 (pt) |
DE (1) | DE60226225T2 (pt) |
ES (1) | ES2301648T3 (pt) |
GB (1) | GB0111078D0 (pt) |
PT (1) | PT1387836E (pt) |
WO (1) | WO2002090346A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1427420T1 (sl) * | 2001-09-12 | 2006-12-31 | Novartis Ag | Uporaba kombinacije, ki vsebuje 4-piridilmetilftalazine za zdravljenje raka |
US7754716B2 (en) | 2002-06-28 | 2010-07-13 | Novartis Ag | Combination comprising a vasculostatic compound and an alkylating agent for the treatment of a tumor |
WO2004058234A2 (en) * | 2002-12-27 | 2004-07-15 | Schering Aktiengesellschaft | Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors |
UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
ATE528302T1 (de) * | 2005-08-29 | 2011-10-15 | Vertex Pharma | 3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin- kinasen nützlich sind |
NZ591820A (en) | 2008-08-27 | 2012-12-21 | Leo Pharma As | Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors |
WO2014076104A1 (en) * | 2012-11-16 | 2014-05-22 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
AU2014241430B2 (en) | 2013-03-14 | 2018-04-26 | Dart Neuroscience (Cayman) Ltd. | Substituted pyridine and pyrazine compounds as PDE4 inhibitors |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE567431A (pt) | 1957-05-07 | |||
GB1293565A (en) * | 1969-05-03 | 1972-10-18 | Aspro Nicholas Ltd | Aminophthalazines and pharmaceutical compositions thereof |
US4665181A (en) * | 1984-05-17 | 1987-05-12 | Pennwalt Corporation | Anti-inflammatory phthalazinones |
JPH03106875A (ja) | 1989-09-20 | 1991-05-07 | Morishita Pharmaceut Co Ltd | 1―(3―ピリジルメチル)フタラジン誘導体 |
EP0600831A1 (de) | 1992-11-27 | 1994-06-08 | Ciba-Geigy Ag | Phthalazinonderivate |
DE69533057T2 (de) * | 1994-08-09 | 2005-06-16 | Eisai Co., Ltd. | Kondensierte pyridazinverbindungen |
EP0876366B1 (en) | 1996-01-15 | 2001-07-25 | Janssen Pharmaceutica N.V. | Angiogenesis inhibiting pyridazinamines |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
ATE329596T1 (de) * | 1999-03-30 | 2006-07-15 | Novartis Pharma Gmbh | Phthalazinderivate zur behandlung von entzündlicher erkrankungen |
AR025068A1 (es) | 1999-08-10 | 2002-11-06 | Bayer Corp | Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis |
-
2001
- 2001-05-04 GB GBGB0111078.2A patent/GB0111078D0/en not_active Ceased
-
2002
- 2002-05-03 PT PT02738031T patent/PT1387836E/pt unknown
- 2002-05-03 JP JP2002587426A patent/JP4365586B2/ja not_active Expired - Fee Related
- 2002-05-03 ES ES02738031T patent/ES2301648T3/es not_active Expired - Lifetime
- 2002-05-03 BR BR0209332-4A patent/BR0209332A/pt not_active IP Right Cessation
- 2002-05-03 CN CNB028092937A patent/CN1314681C/zh not_active Expired - Fee Related
- 2002-05-03 AT AT02738031T patent/ATE393152T1/de active
- 2002-05-03 CA CA002446051A patent/CA2446051A1/en not_active Abandoned
- 2002-05-03 US US10/475,419 patent/US7399761B2/en not_active Expired - Fee Related
- 2002-05-03 WO PCT/EP2002/004892 patent/WO2002090346A1/en active IP Right Grant
- 2002-05-03 EP EP02738031A patent/EP1387836B1/en not_active Expired - Lifetime
- 2002-05-03 DE DE60226225T patent/DE60226225T2/de not_active Expired - Lifetime
-
2008
- 2008-06-18 US US12/141,179 patent/US20090076003A1/en not_active Abandoned
-
2010
- 2010-11-24 US US12/953,837 patent/US8034814B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
GB0111078D0 (en) | 2001-06-27 |
PT1387836E (pt) | 2008-06-27 |
ES2301648T3 (es) | 2008-07-01 |
US7399761B2 (en) | 2008-07-15 |
ATE393152T1 (de) | 2008-05-15 |
JP2004532241A (ja) | 2004-10-21 |
CN1507444A (zh) | 2004-06-23 |
JP4365586B2 (ja) | 2009-11-18 |
WO2002090346A1 (en) | 2002-11-14 |
US20110130399A1 (en) | 2011-06-02 |
CN1314681C (zh) | 2007-05-09 |
CA2446051A1 (en) | 2002-11-14 |
EP1387836A1 (en) | 2004-02-11 |
US20040180899A1 (en) | 2004-09-16 |
EP1387836B1 (en) | 2008-04-23 |
DE60226225T2 (de) | 2009-09-10 |
US8034814B2 (en) | 2011-10-11 |
DE60226225D1 (de) | 2008-06-05 |
US20090076003A1 (en) | 2009-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0407618A (pt) | derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização | |
NO20023218L (no) | 2-amino-nikotinamidderivater og deres anvendelse som VEGF- reseptor tyrosinkinaseinhibitorer | |
BR0010520A (pt) | Novos compostos farmaceuticamente ativos | |
DK1427708T3 (da) | Amino-phthalazinon-derivater som kinase-inhibitorer, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger der indeholder det samme | |
DE69801590T2 (de) | Imidazolderivate und ihre verwendung als farnesylproteintransferase inhibitoren | |
TR199801115T2 (xx) | Kinazolin t�revleri. | |
BR0317717A (pt) | Composto, composição farmacêutica, uso de um composto, método para tratar um humano sofrendo de uma doença, e, processo para a preparação de um composto | |
DE69615674D1 (de) | Cyclobutan-derivate als inhibitoren der squalen-synthase und der protein farnesyltransferase | |
BRPI0409136A (pt) | composto heteroaromático pentacìclico e uso medicinal do mesmo | |
MXPA04012965A (es) | Inhibidores virales. | |
DE60315674D1 (de) | Neue imidazopyridine und ihre verwendung | |
BR0315988A (pt) | Derivados de diidropirimido[4,5-d]pirimidinona substituìda por amino, sua produção e uso como agentes farmacêuticos | |
MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
WO2003048164A3 (en) | Adenosine a2a receptor antagonists | |
MXPA04005209A (es) | Antagonistas del receptor de adenosina a2a. | |
BR0215151A (pt) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
DE60205455D1 (de) | Naphthyridinderivate | |
AR036327A1 (es) | Compuestos derivados del cromano para uso terapeutico, composicion farmaceutica, uso de estos compuestos para la preparacion de medicamentos para tratar migrana, compuestos relacionados, y procesos para preparar esos compuestos relacionados | |
HUP0000189A2 (hu) | Biciklusos aril-karboxamid-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk terápiás célokra | |
BR0113590A (pt) | 7-oxo-piridopirimidinas | |
BR0210392A (pt) | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto | |
DK0669912T3 (da) | N-(3-Piperidinylcarbonyl)-beta-alaninderivater som PAF-antagonister | |
BR0209332A (pt) | Derivados de ftalazina com atividade inibidora da angiogênese | |
BR0211030A (pt) | Derivado de pirrolidina oxadiazole, uso de um derivado de pirrolidina oxadiazole, composição farmacêutica contendo pelo menos um derivado de pirrolidina oxadiazole, método para preparação de um composto de pirrolidina oxadiazole | |
MX2023006881A (es) | Antagonistas del receptor de adenosina a2a. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A E 10A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012. |